Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 4,797,728 shares, a growth of 20.2% from the January 15th total of 3,991,736 shares. Based on an average trading volume of 965,487 shares, the short-interest ratio is presently 5.0 days. Approximately 8.7% of the shares of the stock are short sold. Approximately 8.7% of the shares of the stock are short sold. Based on an average trading volume of 965,487 shares, the short-interest ratio is presently 5.0 days.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $8.59 on Wednesday. The stock has a market capitalization of $483.62 million, a price-to-earnings ratio of 18.28 and a beta of 0.99. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16. The firm has a fifty day simple moving average of $8.67 and a 200 day simple moving average of $9.22. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ZVRA shares. Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Finally, Cantor Fitzgerald decreased their price objective on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.80.

Insider Activity

In other Zevra Therapeutics news, insider Adrian W. Quartel sold 4,533 shares of Zevra Therapeutics stock in a transaction on Friday, January 30th. The stock was sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the transaction, the insider owned 9,723 shares in the company, valued at approximately $85,854.09. The trade was a 31.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the transaction, the senior vice president directly owned 29,590 shares in the company, valued at approximately $271,636.20. This represents a 9.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 114,158 shares of company stock worth $1,062,878. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after buying an additional 1,812 shares during the last quarter. Strs Ohio acquired a new position in shares of Zevra Therapeutics during the 1st quarter worth approximately $125,000. Carret Asset Management LLC raised its stake in Zevra Therapeutics by 9.7% in the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company’s stock valued at $349,000 after acquiring an additional 3,500 shares during the period. Corton Capital Inc. bought a new stake in Zevra Therapeutics in the 2nd quarter valued at $156,000. Finally, Fox Run Management L.L.C. acquired a new stake in Zevra Therapeutics during the 2nd quarter valued at $99,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.